Enduring Material

- https://storage.googleapis.com/rmphtc/Colorado%20Consortium/josh-blum-opioid-tapering/Josh%20Blum%20-%20Opioid%20Reduction%20and%20Discontinuation%20Strategies_player.html

• The effective and safe management of pain is a primary concern for both Colorado healthcare providers and patients. As such, today's prescribers have dual obligations: to effectively manage pain and improve function while reducing opioid-related adverse outcomes such as diversion, addiction, overdose, and death.

• Describe indications for opioid tapering and/or discontinuation;
• Explain how to initiate difficult patient conversations around discontinuing opioids;
• Apply appropriate weaning strategies for patients discontinuing chronic opioid therapy;
• Implement opioid withdrawal management and support strategies into practice; and
• Employ buprenorphine therapy in support of withdrawal management and chronic pain treatment.

• The Colorado Medical Society designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 0.75 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Course video

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Joshua Blum, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Joshua Blum, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity does not have commercial support from any ACCME defined ineligible company. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

100 %

7/24/2024